Regeneron Pharmaceuticals, Inc. (REGN)

Over the past six months, Regeneron's stock experienced volatility and a loss of 18.9%. Regeneron shares jumped 5.3% following positive clinical trial results for Dupixent on March 10, 2025. In Q1 CY2025, Regeneron fell short of market revenue expectations, with sales declining 3.7% year-on-year to $3.03 billion. Citigroup upgraded its outlook for Regeneron Pharmaceuticals from Neutral to Buy on May 14, 2025. Leerink Partners upgraded its outlook for Regeneron Pharmaceuticals from Market Perform to Outperform on February 5, 2025. On July 2, 2025, Regeneron announced that Lynozyfic™ received FDA accelerated approval. UBS raised its price target on Regeneron Pharmaceuticals to $584.00 from $560.00 on July 11, 2025. The stock has been pressured lower due to market concerns about the potential cost of manufacturing a phase 2 weight-loss drug therapy (VK2735).

Information regarding the demand seasonality for Regeneron Pharmaceuticals, Inc.'s products and services is generally analyzed through the company's stock performance seasonality. While specific product demand seasonality is not detailed, the stock's performance can exhibit seasonal trends. Seasonality measures the average change in price over time, with each calendar month showing how frequently it closes higher than the previous month.

Regeneron Pharmaceuticals, Inc. is an American biotechnology company focused on discovering, developing, and commercializing medicines for serious diseases. Headquartered in Tarrytown, New York, Regeneron operates within the Healthcare sector and Biotechnology industry, utilizing proprietary technologies like Trap and VelociSuite platforms. The company's portfolio includes treatments for eye diseases, allergic and inflammatory conditions, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, and infectious and rare diseases. Key products include EYLEA, Dupixent, Libtayo, Praluent, Evkeeza, Inmazeb, Arcalyst, Zaltrap, Kevzara, REGEN-COV, and Lynozyfic™.

Regeneron Pharmaceuticals has a global presence with operations in North America, Europe, and Asia. The company operates in the United States and the Rest of the World, with offices in 12 countries and clinical trials in over 50 countries. Manufacturing units are located in the U.S. (New York) and Ireland (Limerick). Its products are available in countries including the US, the Netherlands, Bermuda, Ireland, Spain, India, Japan, and the UK.

Regeneron has maintained a strong brand reputation, particularly within the scientific and biopharmaceutical communities. Regeneron has been ranked as the top company to work for by Science magazine in its annual Top Employers Survey. The company's science-driven culture and rapid response to health challenges have reinforced its reputation. Regeneron also ranks well on ESG metrics.

Regeneron Pharmaceuticals is primarily owned by institutional shareholders, with a significant portion also held by insiders and a smaller percentage by retail investors. Institutional shareholders own approximately 57.64% to 84.75% of the company's stock, with Vanguard Group Inc. holding the most shares. Insiders own approximately 0.28% to 37.25% of the company, with Sanofi being the largest individual shareholder. Retail investors hold approximately 0.00% to 42.09% of the stock.